MONTREAL, QUEBEC -- (MARKET WIRE) -- April 18, 2007 -- Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that new data on its two anticancer drug candidates, ECO-4601 and CAP-232, have been presented in three poster presentations at the 98th Annual Meeting of the American Association for Cancer Research (AACR), held in Los Angeles April 14-19, 2007.
